Ranibizumab biosimilar (Pfenex)

雷珠单抗生物类似药 (Pfenex)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRanibizumab biosimilar (Pfenex)

Drug Alias Name雷尼比珠单抗生物仿制药（Pfenex）PF-582

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNew Zealand

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfenex Biopharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfenex Inc

Active IndicationsN/A

Inactive IndicationsMacular Degeneration

Other Information

ATC CodeS01LA04